NO302701B1 - Kinuklidin-derivater - Google Patents

Kinuklidin-derivater

Info

Publication number
NO302701B1
NO302701B1 NO934312A NO934312A NO302701B1 NO 302701 B1 NO302701 B1 NO 302701B1 NO 934312 A NO934312 A NO 934312A NO 934312 A NO934312 A NO 934312A NO 302701 B1 NO302701 B1 NO 302701B1
Authority
NO
Norway
Prior art keywords
quinuclidine derivatives
quinuclidine
derivatives
Prior art date
Application number
NO934312A
Other languages
English (en)
Norwegian (no)
Other versions
NO934312L (no
NO934312D0 (no
Inventor
Fumitaka Ito
Hiroshi Kondo
Kaoru Shimada
Masami Nakane
Iii John Adams Lowe
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO302701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO934312L publication Critical patent/NO934312L/no
Publication of NO934312D0 publication Critical patent/NO934312D0/no
Publication of NO302701B1 publication Critical patent/NO302701B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO934312A 1991-05-31 1993-11-29 Kinuklidin-derivater NO302701B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
PCT/US1992/003317 WO1992021677A1 (fr) 1991-05-31 1992-04-28 Derives de quinuclidine

Publications (3)

Publication Number Publication Date
NO934312L NO934312L (no) 1993-11-29
NO934312D0 NO934312D0 (no) 1993-11-29
NO302701B1 true NO302701B1 (no) 1998-04-14

Family

ID=24845673

Family Applications (2)

Application Number Title Priority Date Filing Date
NO934312A NO302701B1 (no) 1991-05-31 1993-11-29 Kinuklidin-derivater
NO2007003C NO2007003I2 (no) 1991-05-31 2007-03-09 Maropitant eller et farmasøytisk akseptabelt salt av denne forbindelsen, inkludert citrat monohydratsalt

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2007003C NO2007003I2 (no) 1991-05-31 2007-03-09 Maropitant eller et farmasøytisk akseptabelt salt av denne forbindelsen, inkludert citrat monohydratsalt

Country Status (41)

Country Link
US (3) US5807867A (fr)
EP (1) EP0587723B1 (fr)
JP (2) JPH0733386B2 (fr)
KR (1) KR100214905B1 (fr)
CN (1) CN1048492C (fr)
AP (1) AP299A (fr)
AT (1) ATE135006T1 (fr)
AU (1) AU657552B2 (fr)
BG (1) BG61694B1 (fr)
BR (1) BR9206073A (fr)
CA (1) CA2102179C (fr)
CZ (1) CZ281403B6 (fr)
DE (4) DE69208877T2 (fr)
DK (1) DK0587723T3 (fr)
EG (1) EG19944A (fr)
ES (1) ES2084361T3 (fr)
FI (1) FI114475B (fr)
GR (1) GR3019687T3 (fr)
GT (1) GT199200028A (fr)
HU (1) HU217548B (fr)
IE (1) IE72473B1 (fr)
IL (1) IL102008A (fr)
IS (1) IS1611B (fr)
LU (1) LU91293I2 (fr)
MA (1) MA22539A1 (fr)
MX (1) MX9202554A (fr)
NL (1) NL300250I2 (fr)
NO (2) NO302701B1 (fr)
NZ (2) NZ242956A (fr)
OA (1) OA09867A (fr)
PL (1) PL171379B1 (fr)
PT (1) PT100546B (fr)
RO (1) RO110499B1 (fr)
RU (1) RU2103269C1 (fr)
SK (1) SK390692A3 (fr)
TW (1) TW204349B (fr)
UA (1) UA27776C2 (fr)
UY (1) UY23422A1 (fr)
WO (1) WO1992021677A1 (fr)
YU (1) YU48995B (fr)
ZA (1) ZA923942B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69208877T2 (de) * 1991-05-31 1996-07-25 Pfizer Chinuclidinderivate
CZ290475B6 (cs) * 1991-06-20 2002-07-17 Pfizer Inc. Fluoralkoxybenzylaminové deriváty heterocyklů obsahujících dusík, způsob jejich přípravy, meziprodukty tohoto postupu a pouľití těchto derivátů
EP1114823A3 (fr) * 1992-08-19 2001-07-18 Pfizer Inc. Benzylamino azote substitue renfermant des heterocycles non aromatiques
DE69307340T2 (de) * 1992-11-12 1997-04-24 Pfizer Chinuclidin derivat als substanz p antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (fr) * 1993-11-17 1995-10-11 Pfizer Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
EP0659409A3 (fr) * 1993-11-23 1995-08-09 Pfizer Antagonistes de la substance P pour l'inhibition de l'angiogénése.
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
CN1291099A (zh) * 1998-03-19 2001-04-11 武田药品工业株式会社 杂环化合物,其生产和用途
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
CA2324116A1 (fr) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Antagonistes du recepteur nk-1 et eletriptan pour le traitement de la migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
CA2415532C (fr) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Nouvelles tetrahydroisoquinolines 4-phenyl substituees et leur utilisation a des fins therapeutiques
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
PL367944A1 (en) * 2001-07-20 2005-03-07 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2005045395A2 (fr) * 2003-10-27 2005-05-19 Meyer Donald W Methode de detection de l'encephalopathie spongiforme bovine
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
CN1913893A (zh) * 2004-01-30 2007-02-14 辉瑞产品有限公司 改善麻醉恢复的nk－1受体拮抗剂
ATE380811T1 (de) * 2004-02-02 2007-12-15 Pfizer Prod Inc Verfahren zur herstellung von 1-(2s,3s)-2- benzhydril-n-(5-tert.-butyl-2- methoxybenzyl)chinuklidin-3-amin
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (fr) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
CA2690191C (fr) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase
CA2717509A1 (fr) 2008-03-03 2009-09-11 Tiger Pharmatech Inhibiteurs de la tyrosine kinase
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CA2760837C (fr) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et son utilisation
CA2777043C (fr) 2009-10-14 2015-12-15 Schering Corporation Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (fr) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
WO2013004766A1 (fr) 2011-07-04 2013-01-10 Ferrari Giulio Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (fr) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
CN110730662A (zh) 2017-04-10 2020-01-24 才思治疗公司 用于治疗共核蛋白病的nk1-拮抗剂组合和方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP4371613A3 (fr) 2018-02-26 2024-07-24 Ospedale San Raffaele S.r.l. Composés destinés à être utilisés dans le traitement de la douleur oculaire
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2021180885A1 (fr) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Traitement d'une déficience en cellules souches

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (fr) * 1988-11-23 1990-05-31 Pfizer Inc. Derives de quinuclidine en tant qu'antagonsites de substance p
ES2063507T3 (es) * 1990-06-01 1995-01-01 Pfizer 3-amino-2-aril-quinuclidinas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
DE69208877T2 (de) * 1991-05-31 1996-07-25 Pfizer Chinuclidinderivate
PT533280E (pt) * 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ES2147889T3 (es) * 1996-01-19 2000-10-01 Lonza Ag Metodo para preparar 3-hidroxiquinuclidinol opticamente activo.
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
EP0587723B1 (fr) 1996-03-06
JPH0733386B2 (ja) 1995-04-12
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
NZ270673A (en) 1997-07-27
GR3019687T3 (en) 1996-07-31
UA27776C2 (uk) 2000-10-16
PL171379B1 (en) 1997-04-30
JPH07285965A (ja) 1995-10-31
AU1990192A (en) 1993-01-08
CA2102179C (fr) 1998-10-27
CZ281403B6 (cs) 1996-09-11
DE69208877T2 (de) 1996-07-25
ES2084361T3 (es) 1996-05-01
AP299A (en) 1994-01-14
JPH06504292A (ja) 1994-05-19
IL102008A (en) 1995-12-08
IL102008A0 (en) 1992-12-30
CA2102179A1 (fr) 1992-12-01
NO934312L (no) 1993-11-29
BG98248A (bg) 1994-07-29
TW204349B (fr) 1993-04-21
AP9200384A0 (en) 1992-07-31
SK278788B6 (sk) 1998-02-04
DE122006000066I2 (de) 2007-12-06
YU48995B (sh) 2003-04-30
FI114475B (fi) 2004-10-29
UY23422A1 (es) 1992-11-12
JP2645225B2 (ja) 1997-08-25
WO1992021677A1 (fr) 1992-12-10
IE72473B1 (en) 1997-04-23
CN1048492C (zh) 2000-01-19
ATE135006T1 (de) 1996-03-15
FI935297A (fi) 1993-11-29
YU56492A (sh) 1995-03-27
NZ242956A (en) 1995-06-27
DK0587723T3 (da) 1996-04-01
EP0587723A1 (fr) 1994-03-23
FI935297A0 (fi) 1993-11-29
CZ390692A3 (en) 1994-02-16
HU9303393D0 (en) 1994-03-28
HU217548B (hu) 2000-02-28
NL300250I1 (nl) 2007-02-01
KR100214905B1 (ko) 1999-08-02
US5939433A (en) 1999-08-17
IE921729A1 (en) 1992-12-02
NL300250I2 (nl) 2007-03-01
NO2007003I1 (no) 2007-03-26
US5807867A (en) 1998-09-15
DE69208877D1 (de) 1996-04-11
RU2103269C1 (ru) 1998-01-27
GT199200028A (es) 1993-11-20
IS3871A (is) 1992-12-02
RO110499B1 (ro) 1996-01-30
PT100546B (pt) 1999-12-31
CN1067428A (zh) 1992-12-30
MA22539A1 (fr) 1992-12-31
IS1611B (is) 1996-10-18
DE122006000066I1 (de) 2007-03-22
BG61694B1 (bg) 1998-03-31
NO934312D0 (no) 1993-11-29
PT100546A (pt) 1993-08-31
SK390692A3 (en) 1998-02-04
BR9206073A (pt) 1994-12-06
AU657552B2 (en) 1995-03-16
ZA923942B (en) 1993-11-29
US6222038B1 (en) 2001-04-24
EG19944A (en) 1997-02-27
HUT70151A (en) 1995-09-28
MX9202554A (es) 1992-11-01
NO2007003I2 (no) 2011-04-18
DE9290063U1 (de) 1994-02-24

Similar Documents

Publication Publication Date Title
DK0587723T3 (da) Quinuclidinderivater
NO922182D0 (no) Krystallinske oksatiolan-derivater
FI920718A (fi) Vaetskefoerdelare med indraget foerdelningsmunstycke
NO924890D0 (no) Imidazopyridiner
FI925763A0 (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
FI923541A (fi) Schaberanordning med schaberbalk
FI920440A (fi) Squid-maetningsanordning foersedd med skyddsorgan
FI912993A0 (fi) Teline
FI922774A (fi) Effektfaktorkorrigerande enstegsomvandlare med en isolerad utgaong
DE69222599D1 (de) Cephalosporin-Derivate
NO920420L (no) 3-quinuklidin-derivater
DE59207540D1 (de) Resolver
FI88322B (fi) Med ledbommar foersedd arbetsmaskin
FI930110A (fi) Dieseloljor med laog svavelhalt innehaollande organometalliska komplex
FI925469A (fi) Tiazolylsubstituerade kinolylymetoxifenylaettiksyraderivat
MX9206710A (es) Derivados de piridinol
FI921921A (fi) Hydrocyklonseparator med turbulensskydd
FI912080A (fi) Lagringslaoda foersedd med en gavelvaeggen slutande genomsynlig klaffskiva
FI920393A (fi) Radio- och landfoerbindelsetelefoner med hands-free-funktion
FI921597A (fi) Maetning av en hisskorgs position med hjaelp av ultraljud
FI920834A (fi) Med fukos maerkta cytostater
DE69211197D1 (de) 1-Hydroxyvitamin D-Derivate
KR930702353A (ko) 2- 카르바페넴 유도체
FI920953A (fi) Belaeggningskopp med tvao ingaongar foer fiberbandkabel

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: CERENIA-MAROPITANT; NAT. REG. NO/DATE: EU206062001/NO-005/NO 20061031; FIRST REG. NO/DATE: BE , EU206062001-005 20060929

Spc suppl protection certif: 2007003

Filing date: 20070309

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: CERENIA-MAROPITANT; NAT. REG. NO/DATE: EU206062001/NO-005/NO 20061031; FIRST REG. NO/DATE: BE , EU206062001-005 20060929

Spc suppl protection certif: 2007003

Filing date: 20070309

Extension date: 20170428

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2007003